Active Covid-19 Cases Cross 300-Mark In Karnataka, Authorities On Alert
Karnataka's Health and Family Welfare Department has said in an official statement that the number of active Covid-19 cases crossed the 300-mark in the state.
As the most of the schools reopened on Monday after summer vacations, the authorities are on high alert.
The number of total active Covid-19 patients reached 311, with 87 persons testing positive for the infection in the last 24 hours, the Health and Family Welfare department said on Monday.
As many as 504 persons were tested across the state.
A total of 29 persons were discharged during the same period.
The Covid-positivity rate stood at 17.2 per cent and case fatality rate is zero per cent.
Among the total 311 patients, 297 are kept in home quarantine and 14 admitted to hospitals, three are in Intensive Care Units of the government and private hospitals.
Amid the fear of Covid-19, the authorities are worried over the increasing number of the Severe Acute Respiratory Infection (SARI) and influenza cases.
According to sources in the Health department, the total number of SARI and influenza cases have increased to 4,536 cases in the state since January this year.
In the last week, 154 SARI cases have been reported in the state.
The officials said that they are seeing a trend of steep rise in number of such cases.
The government is arranging for Covid-19 tests for the patients affected with SARI and influenza.
The doctors have warned people not to neglect the symptoms of fever, cough, fatigue, nose blockage, running nose, headache, breathing issues, and throat pain.
The capital Bengaluru continues to be hotspot for Covid-19 as most active cases are reported from here.
Meanwhile, State Health Minister Dinesh Gundu Rao said that the Gruha Arogya Yojana (Home Health Scheme) is being expanded across the state, with 14 non-communicable diseases included for screening under the programme.
The Minister added that non-communicable diseases pose a significant threat to people's lives.
While the private healthcare sector prioritises treatment, it is crucial to prevent non-communicable diseases proactively.
He emphasised that the government should undertake this task, as others may not show interest.
As a responsible government, the State Health Department is expanding the Gruha Arogya Yojana statewide to prevent non-communicable diseases, the Minister said.
Minister Rao also added that the programme will screen individuals aged above 30 years in every household and ensure that appropriate medicines reach them.
The project was implemented in Kolar district initially.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
20 minutes ago
- Time of India
Moderna layoffs: U.S. Pharma giant announces massive job cuts, to have less than 5,000 employees, MRNA stocks sink
Moderna said on Thursday it would trim roughly 10 per cent of its global workforce and have fewer than 5,000 employees by the end of the year, as the biotech accelerates its cost-cutting efforts amid declining sales of COVID-19 vaccines. The move, announced in an internal memo by CEO Stephane Bancel, is part of the company's previous plan to cut operating expenses by about $1.5 billion by 2027. "We've made significant progress by scaling down R&D as respiratory trials conclude, renegotiating supplier agreements, and reducing manufacturing costs," Bancel said in the memo. Explore courses from Top Institutes in Please select course: Select a Course Category MCA healthcare Leadership Technology Healthcare Project Management Data Science PGDM Public Policy Product Management CXO Artificial Intelligence Degree Digital Marketing Design Thinking Finance MBA Operations Management Data Analytics others Others Data Science Management Cybersecurity Skills you'll gain: Programming Proficiency Data Handling & Analysis Cybersecurity Awareness & Skills Artificial Intelligence & Machine Learning Duration: 24 Months Vellore Institute of Technology VIT Master of Computer Applications Starts on Aug 14, 2024 Get Details Moderna had said earlier this year it expects operating costs to be between $4.7 billion and $5 billion for 2027. The Cambridge, Massachusetts-based biotech has been banking on revenue from newer mRNA shots, including its experimental COVID-flu combination vaccine, to make up for falling sales of its COVID-19 shot and less-than-expected uptake of its respiratory syncytial virus vaccine. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Calcutta: 1 Trick to Reduce Belly Fat? Home Fitness Hack Shop Now Undo Moderna MRNA Stocks But investor concerns about the prospects of new shots and the changes in vaccine policy under U.S. Health Secretary and vaccine skeptic Robert F. Kennedy Jr. have led to a more than 20 per cent decline in Moderna's shares this year. Live Events The stock, which has lost more than 90 per cent of its value since the pandemic-era highs, was trading about 4 per cent down on Thursday. Moderna had said in May it did not expect regulatory approval for its combination shot until 2026, since the U.S. Food and Drug Administration asked for late-stage data showing the vaccine's efficacy against the flu. The company had previously hoped to launch the vaccine for the autumn respiratory disease season in 2025 or 2026. Bancel in the memo reiterated the company's target to have eight more approvals for its products in the next three years. FAQs Q1. Is Moderna laying off workforce? A1. Moderna said on Thursday it would trim roughly 10 per cent of its global workforce. Q2. What are Moderna's operating costs? A2. Moderna had said earlier this year it expects operating costs to be between $4.7 billion and $5 billion for 2027.
Time of India
20 minutes ago
- Time of India
Moderna plans to lay off 10% of workforce to cut costs
Moderna said on Thursday it would trim roughly 10% of its global workforce and have fewer than 5,000 employees by the end of the year, as the biotech accelerates its cost-cutting efforts amid declining sales of COVID-19 vaccines. The move, announced in an internal memo by CEO Stephane Bancel , is part of the company's previous plan to cut operating expenses by about $1.5 billion by 2027. Explore courses from Top Institutes in Please select course: Select a Course Category Operations Management Finance MCA Data Science Healthcare Public Policy Digital Marketing CXO Project Management PGDM Technology Artificial Intelligence Product Management healthcare Degree MBA Data Science others Management Leadership Data Analytics Cybersecurity Others Design Thinking Skills you'll gain: Quality Management & Lean Six Sigma Analytical Tools Supply Chain Management & Strategies Service Operations Management Duration: 10 Months IIM Lucknow IIML Executive Programme in Strategic Operations Management & Supply Chain Analytics Starts on Jan 27, 2024 Get Details "We've made significant progress by scaling down R&D as respiratory trials conclude, renegotiating supplier agreements, and reducing manufacturing costs," Bancel said in the memo. Moderna had said earlier this year it expects operating costs to be between $4.7 billion and $5 billion for 2027. The Cambridge, Massachusetts-based biotech has been banking on revenue from newer mRNA shots, including its experimental COVID-flu combination vaccine, to make up for falling sales of its COVID-19 shot and less-than-expected uptake of its respiratory syncytial virus vaccine. Live Events But investor concerns about the prospects of new shots and the changes in vaccine policy under U.S. Health Secretary and vaccine skeptic Robert F. Kennedy Jr. have led to a more than 20% decline in Moderna's shares this year. The stock, which has lost more than 90% of its value since the pandemic-era highs, was trading about 4% down on Thursday. Moderna had said in May it did not expect regulatory approval for its combination shot until 2026, since the U.S. Food and Drug Administration asked for late-stage data showing the vaccine's efficacy against the flu. The company had previously hoped to launch the vaccine for the autumn respiratory disease season in 2025 or 2026. Bancel in the memo reiterated the company's target to have eight more approvals for its products in the next three years.
India Today
36 minutes ago
- India Today
What forced Vinay Prasad to exit top job at US FDA in just 3 months
The US Food and Drug Administration's (FDA) top vaccine official, Vinay Prasad, stepped down in less than three months after his appointment, following intense scrutiny over his regulatory decisions and political attacks from conservative activists. His stringent oversight of biopharmaceutical company Sarepta Therapeutics' gene therapy for Duchenne Muscular Dystrophy (DMD), a severe genetic disorder, sparked backlash from patient groups and investors, while his approach also raised concerns among biotech firms about innovation, clashing with FDA priorities, according to reports in US-based media an oncologist who was a fierce critic of the US COVID-19 vaccine and mask mandates, was appointed in May by FDA Commissioner Marty Makary. Together, they promised to speed regulatory action and pilot new review pathways, news agency Reuters he faced mounting scrutiny over his decision to pause shipments of Sarepta's Elevidys, a gene therapy for DMD, after three patient deaths raised safety concerns, Reuters reported. The FDA, on July 18, asked Sarepta to stop all shipments of the approved DMD therapy, citing safety FDA's decision to halt shipments sparked outrage from patient groups and biotech investors, who argued the therapy's benefits for a fatal disease were July 28, the FDA reversed course, allowing shipments to resume for ambulatory regulatory approach and the absence of clearly defined standards prompted concern within parts of the biotech industry, with some suggesting it could impact investment and innovation – raising questions about alignment with Marty Makary's priorities, according to an op-ed in the Wall Street Journal (WSJ).The agency's lack of clear, predictable standards under Prasad was creating enormous uncertainty for the industry, especially small biotech companies, and threatened to chill investment, according to the inflexible position on the design of clinical trials also risked slowing and raising costs for drug development. This is the opposite of what Marty Makary says he wants to do, the WSJ op-ed Republican Senator Rick Santorum, who has connections to Sarepta Therapeutics, reportedly contacted senior White House officials to express concerns over Prasad's attempts to restrict the use of Elevidys, Daily Beast reported, citing The has maintained that its treatment was not responsible for the reported deaths. Prior to joining the FDA, Dr Prasad had voiced criticism of the company, and following his appointment, Sarepta's stock dropped by nearly 25%, according to people familiar with the situation told the Associated Press (AP) that Prasad was ousted following several recent joined the FDA in May after years as an academic researcher at the University of California, San Francisco, where he frequently criticised the FDA's approach to drug approvals and Covid-19 vaccines, AP PRASAD RESIGNS TO AVOID DISTRACTIONA Department of Health and Human Services spokesperson told CNN on July 29 that Vinay Prasad resigned to avoid being a "distraction" to the agency's work under the Trump administration, choosing to return to California to spend more time with his Prasad did not want to be a distraction to the great work of the FDA in the Trump administration and has decided to return to California and spend more time with his family," the spokesperson told the Prasad was also given the role of FDA chief medical and scientific several health officials later appointed under the Trump administration, Prasad had previously been outspoken in his criticism of the government's handling of the Covid-19 pandemic and its vaccine departure came amid fresh pressure from the White House for him to resign, according to a person familiar with the matter who was granted anonymity to describe the internal dynamics, and followed days of criticism from Laura Loomer, a right-wing activist with extraordinary access to President Donald Trump, CNN July 20, Loomer, a close Trump supporter, published a blog post accusing Prasad of being a "progressive leftist saboteur" and claiming he was actively working against the mission of the former administration officials and advisers, from campaign strategists to public health voices, faced public targeting by Loomer before being sidelined or dismissed by who called herself an investigative journalist, has built a reputation for aggressive rhetoric, confrontational tactics, and a social media presence that thrives on Loomer has no formal role in Donald Trump's campaign or political machinery, her influence seems to travel in parallel with the MAGA ecosystem. Several former administration officials and advisers – ranging from campaign strategists to public health voices – have found themselves publicly targeted by Loomer shortly before being sidelined or dismissed by Trump or his inner days before his resignation, the FDA Commissioner publicly defended Prasad, telling Politico that he is "an impeccable scientist" and "one of the greatest scientific minds of our generation."Prasad also drew criticism from former officials and vaccine experts after internal memos from May revealed that he overrode FDA scientists on recommendations for two new versions of COVID-19 vaccines, CNN reported.- EndsMust Watch
